低分子肝素钙治疗慢性肺源性心脏病合并呼吸衰竭临床研究  

Clinical Study of Low Molecular Weight Heparin Calcium in the Treatment of Chronic Pulmonary Heart Disease Complicated With Respiratory Failure

作　　者：范远威[1] 王永[1] 朱宝山[1] 

机构地区：[1]江苏省新沂市铁路医院呼吸内科,江苏新沂221400

出　　处：《中国继续医学教育》2017年第16期156-158,共3页China Continuing Medical Education

摘　　要：目的探讨低分子肝素钙治疗慢性肺源性心脏病合并呼吸衰竭临床效果。方法将本院住院治疗的110例肺心病合并呼吸衰竭患者随机分成观察组与对照组,各55例,对照组给予常规治疗,观察组加用低分子肝素钙治疗,对比其疗效。结果观察组的总有效率为96.4%(53/55),对照组为85.5%(47/55),观察组总有效率高于对照组(P<0.05);两组治疗后动脉血二氧化碳分压均明显下降,用力肺活量、1秒钟用力呼气容积及动脉血氧分压均明显升高,观察组改善更明显(P<0.01)。结论低分子肝素钙治疗肺心病合并呼吸衰竭临床效果满意,值得推行。Objective To investigate the clinical effect of low molecular weight heparin calcium in the treatment of chronic pulmonary heart disease complicated with respiratory failure. Methods The treatment of 110 casesof patients with pulmonary heart disease combined with respiratory failure were randomly divided into observation group and control group in our hospital, 55 cases in each, the control group was given routine treatment, the observation group added with low molecular weight heparin treatment, the curative effect contrast. Results The total effective rate was 96.4%（53/55） in the observation group and 85.5% in the control group（47/55）. The total effective rate of the observation group was higher than that of the control group（P〈0.05）; The carbon dioxide partial pressure of arterial blood decreased obviously in the two groups, and the forced vital capacity, the forced expiratory volume in 1 seconds and the arterial partial pressure of oxygen increased significantly, and the improvement in the observation group was more obvious（P〈0.01）. Conclusion The clinical effect of low molecular weight heparin calcium in the treatment of pulmonary heart disease complicated with respiratory failure is satisfactory. It is worth carrying out.

关 键 词：低分子肝素钙 慢性肺源性心脏病 呼吸衰竭 

分 类 号：R56[医药卫生—呼吸系统]